GO
Loading...

Enter multiple symbols separated by commas

Stocks Abbott Laboratories

More

  • April 22- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.

  • April 22- Abbott Laboratories' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million,...

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • MUMBAI, April 15- India may go to the World Trade Organisation if the European Union does not reconsider a decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • MUMBAI, April 15- India may go to the World Trade Organization if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd, the firm's CEO said. The European Medicines Agency suspension became effective in January, a month after France, Germany, Belgium...

  • Your first trade for Thursday Wednesday, 8 Apr 2015 | 6:14 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Cramer Remix: It's time to buy these oil stocks Wednesday, 1 Apr 2015 | 7:00 PM ET
    Jim Cramer on the set of Mad Money

    The pain may finally be coming to an end for these names, says “Mad Money” host Jim Cramer.

  • Cramer: Watch out! Market's No.1 enemy right now Wednesday, 1 Apr 2015 | 6:12 PM ET
    GoDaddy CEO Blake Irving visits on the floor of the New York Stock Exchange as the website hosting service makes its initial public offering (IPO) on April 1, 2015 in New York.

    Jim Cramer is concerned with the amount of flooding in the market right now, and warns investors to watch out for these signs of a sinking ship.

  • Early movers: SHLD, WMT, GDDY, AAPL & more Wednesday, 1 Apr 2015 | 7:47 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • No bans on NZ dairy products after poison threat -govt Thursday, 12 Mar 2015 | 2:41 AM ET

    Countries including China, the biggest buyer of New Zealand dairy products, were not closing the door on shipments, a top official from the ministry told Reuters, as police track down the sender of letters to dairy giant Fonterra and the national farmers' group which were accompanied by infant formula laced with the pesticide 1080.. Following the announcement...

  • Four trades to go before the closing bell Wednesday, 11 Mar 2015 | 1:29 PM ET

    The "Halftime Report" traders give their final trades of the show.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • *Best Buy climbs after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. It's predicated on the fact that when you get up around new highs market participants tend to get a little vertigo, "said Art Hogan, chief market strategist at Wunderlich Securities in New York.

  • *Best Buy climbs in premarket after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. "The market is naturally settling in, taking a breather until the scales tip either way to commence the next move to continued to new heights or a consolidated pullback," said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • March 2- Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Abbott Labs 2015 outlook in line with estimates Thursday, 29 Jan 2015 | 11:05 AM ET
    Employees walk near an Abbott Laboratories sign at the company's headquarters complex in Abbott Park, Illinois.

    Abbott Laboratories forecast full-year profit in line with analysts' estimates even as other drugmakers warned of a strong dollar hurting results.